Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01358357 · ClinicalTrials.gov registry record · Phase 3
Bipolar Maintenance Study of Lurasidone Adjunctive to Lithium or Divalproex
A Phase 3 study of Bipolar I Disorder, sponsored by Sumitomo Pharma America.
- Completed
- Registry status
- Phase 3
- Development phase
- 965
- Enrollment target
- 20
- Study locations
NCT01358357: Completed Phase 3 study of Bipolar I Disorder, sponsored by Sumitomo Pharma America.
NCT01358357 is a Phase 3 study of Bipolar I Disorder that has completed, run by Sumitomo Pharma America. The registered enrollment target is 965 participants, above the 293-participant average among 26 other Bipolar I Disorder trials with a reported enrollment target (229% higher). The trial reports 20 study locations across 10 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01358357, a Phase 3 study of Bipolar I Disorder, has completed, sponsored by Sumitomo Pharma America.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 965 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is a multi-center, randomized, placebo-controlled, flexible-dose, parallel-group study designed to evaluate the efficacy and safety of lurasidone (in combination with lithium or divalproex) for the maintenance treatment of bipolar I disorder in subjects with or without rapid cycling and /or psychotic features.
Primary Outcome
A mood event is defined as one of the following during the double-blind phase: (1) Fulfilled Diagnostic and Statistical Manual of Mental Disorders, 4th Ed., Text Revision (DSM-IV-TR) criteria for manic, mixed manic, hypomanic, or depressive episode. (2) Required treatment intervention for manic, mixed manic, hypomanic, or depressive symptoms with any antipsychotic (other than study drug), antidepressant, mood stabilizer (other than lithium or divalproex), anxiolytic agents, benzodiazepine (beyo
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Lurasidone
Study Locations (20)
California
- Behavioral Research Specialists, LLC - Glendale
- AXIS Clinical Trials - Los Angeles
- Excell Research, Inc. - Oceanside
- Stanford University School of Medicine Research Program VA Palo Alto Health Care System - Palo Alto
- SF-CARE, Inc. - San Francisco
- Neuropsychiatric Research Center of Orange County - Santa Ana
- "Stanford University School of Medicine - Stanford
Florida
- Florida Clinical Research LLC - Bradenton
- Clinical Neuroscience Solutions, Inc. - Jacksonville
- Galiz Research - Miami Springs
- Clinical Neuroscience Solutions - Orlando
New York
- Village Clinical Research Inc, - New York
- Finger Lakes Clinical Research - Rochester
Alabama
- Harmonex Neuroscience Research - Dothan
Georgia
- Atlanta Center for Medical Research - Atlanta
Indiana
- Clinco - Terre Haute
Massachusetts
- ActivMed Practices & Research Inc. - Haverhill
Missouri
- Psych Care Consultants Research - St Louis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 965 participants |
| Start Date | 2011-06 |
| Est. Completion | 2015-04 |
| Phase | Phase 3 |
What the finished NCT01358357 record still lists
NCT01358357 is an interventional study that assigns participants to a tested intervention. The registered 965 participants enrollment target is mid-sized for trials with a published cap, above the 293-participant average among 26 other Bipolar I Disorder trials with a reported enrollment target (229% higher).
The record links to 1 condition, with Bipolar I Disorder appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT01358357 names 20 study sites across 10 states, led by California, Florida, New York.
Frequently Asked Questions
What is clinical trial NCT01358357 about?
NCT01358357 is a clinical study titled "Bipolar Maintenance Study of Lurasidone Adjunctive to Lithium or Divalproex". This is a multi-center, randomized, placebo-controlled, flexible-dose, parallel-group study designed to evaluate the efficacy and safety of lurasidone (in combination with lithium or divalproex) for the maintenance treatment of bipolar I disorder in subjects with or without rapid cycling and /or psy...
What is the current status of trial NCT01358357?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 965 participants. The study started on 2011-06. Estimated completion is 2015-04.
What conditions does trial NCT01358357 study?
This clinical trial studies the following conditions: Bipolar I Disorder.
What interventions are being tested in trial NCT01358357?
The interventions under investigation include: Placebo (DRUG), Lurasidone (DRUG).
Who is sponsoring clinical trial NCT01358357?
This trial is sponsored by Sumitomo Pharma America, which has 168 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01358357 being conducted?
This trial has 20 study locations across Alabama, California, Florida, Georgia, Indiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Bipolar I Disorder
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01358357's enrollment target sits among peer trials
965 2nd of 26 the highest of 26 other Bipolar I Disorder trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Bipolar I Disorder trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Assess Change in Disease Activity and Adverse Events (AEs) With Cariprazine in the Treatment of Depressive Episodes in Pediatric Participants Participants (10 to 17 Years of Age) With Bipolar I Disorder.
RECRUITING · Phase 3
-
Study to Evaluate Weight Gain as Assessed by Change in BMI Z-score in Pediatric Subjects With Schizophrenia or Bipolar I Disorder
RECRUITING · Phase 3
-
A Randomized Study of Azetukalner Versus Placebo in Depressive Episodes Associated With Bipolar I or II Disorder (Bipolar Depression)
RECRUITING · Phase 3
-
Long-term Safety and Tolerability of Cariprazine for Bipolar I Disorder
COMPLETED · Phase 3
-
A Study of Aripiprazole in Patients With Bipolar I Disorder With a Major Depressive Episode
COMPLETED · Phase 3
-
Open-Label, Flexible-dose Study to Evaluate the Long-Term Safety and Tolerability of Cariprazine in the Treatment of Pediatric Participants With Schizophrenia, Bipolar I Disorder, or Autism Spectrum Disorder
COMPLETED · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05354141 · 970 participants · Phase 3
Extracellular Vesicle Treatment for Acute Respiratory Distress Syndrome (ARDS) (EXTINGUISH ARDS)
- NCT04726241 · 960 participants · Phase 1
The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study
- NCT05142384 · 960 participants · NA
ICBT (Internet Based Cognitive Behavioral Therapy) for Maternal Depression: Community Implementation in Head Start
- NCT05178498 · 960 participants
Impact of Dietary Inflammatory Potential on Breast Cancer Risk
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia